Imaging amyloid pathology in the living brain

Nobuyuki Okamura, Shozo Furumoto, Hiroyuki Arai, Ren Iwata, Kazuhiko Yanai, Yukitsuka Kudo

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)


Progressive deposition of amyloid plaques in the brain which begine before the appearance of cognitive decline, is an initiating event in the pathogenesis of Alzheimer's disease. Therefore, noninvasive detection of amyloid pathology is important for presymptomatic diagnosis and preventive therapy for Alzheimer's disease. Recent research advances have enabled the in vivo imaging of amyloid pathology in humans using nuclear medicine technology. Several amyloid-binding agents have been developed and evaluated by positron emission tomography (PET) and single photon emission computed tomography (SPECT) for their use as contrast agents. Available clinical evidence, indicates that amyloid imaging enables the early diagnosis of Alzheimer's disease with high accuracy and suggests its usefulness for the prediction of progression to Alzheimer's disease in subjects with mild cognitive impairment and probably also in cognitively normal individuals. Another application of this technology is as a surrogate marker for monitoring brain amyloid. In this review, we describe recent progress in the development ot amyloid imaging technology and human clinical trials.

Original languageEnglish
Pages (from-to)56-62
Number of pages7
JournalCurrent Medical Imaging Reviews
Issue number1
Publication statusPublished - 2008 Feb 1


  • Alzheimer's disease
  • Amyloid
  • Molecular imaging
  • Neurofibrillary tangle
  • Positron emission tomography (PET)
  • Senile plaque

ASJC Scopus subject areas

  • Internal Medicine
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Imaging amyloid pathology in the living brain'. Together they form a unique fingerprint.

Cite this